GNLX Stock Summary and Trading Ideas (Genelux | NASDAQ:GNLX)

Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.

Genelux trades on the NASDAQ stock market under the symbol GNLX.

As of August 27, 2026, GNLX stock price climbed to $2.92 with 343,418 million shares trading.

GNLX has a beta of 1.71, meaning it tends to be more sensitive to market movements. GNLX has a correlation of 0.06 to the broad based SPY ETF.

GNLX has a market cap of $132.12 million. This is considered a Micro Cap stock.

In the last 3 years, GNLX traded as high as $30.44 and as low as $1.60.

The top ETF exchange traded funds that GNLX belongs to (by Net Assets): VTI, VXF, IWC.

GNLX has underperformed the market in the last year with a return of -23.0%, while the SPY ETF gained +20.6%. In the last 3 month period, GNLX fell short of the market, returning -3.0%, while SPY returned +2.9%. However, in the most recent 2 weeks GNLX has outperformed the stock market by returning +8.1%, while SPY returned -0.2%.

GNLX support price is $2.60 and resistance is $2.87 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GNLX shares will trade within this expected range on the day.